Next Article in Journal
HPV Vaccines? Still Needed
Previous Article in Journal
Approach to Fever Assessment in Ambulatory Cancer Patients Receiving Chemotherapy: A Clinical Practice Guideline
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 23
Issue 4
10.3747/co.22.2741
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Editorial

Cost-Effectiveness of Pazopanib: An Example of Improved Transparency and Accessibility of Industry-Sponsored Economic Evaluations through Publication in Peer-Reviewed Journals

by
J. Beca
1 and
K.K.W. Chan
2,*
1
Pharmacoeconomics Research Unit, Cancer Care Ontario, and Canadian Centre for Applied Research in Cancer Control, Toronto, ON, Canada
2
Sunnybrook Odette Cancer Centre, Canadian Centre for Applied Research in Cancer Control, and Department of Medicine, University of Toronto, Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2016, 23(4), 327-329; https://0-doi-org.brum.beds.ac.uk/10.3747/co.22.2741
Submission received: 9 May 2016 / Revised: 8 June 2016 / Accepted: 8 July 2016 / Published: 1 August 2016

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

We congratulate Amdahl et al. on publishing their paper about the cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma (mrcc) in Canada. [...]

Share and Cite

MDPI and ACS Style

Beca, J.; Chan, K.K.W. Cost-Effectiveness of Pazopanib: An Example of Improved Transparency and Accessibility of Industry-Sponsored Economic Evaluations through Publication in Peer-Reviewed Journals. Curr. Oncol. 2016, 23, 327-329. https://0-doi-org.brum.beds.ac.uk/10.3747/co.22.2741

AMA Style

Beca J, Chan KKW. Cost-Effectiveness of Pazopanib: An Example of Improved Transparency and Accessibility of Industry-Sponsored Economic Evaluations through Publication in Peer-Reviewed Journals. Current Oncology. 2016; 23(4):327-329. https://0-doi-org.brum.beds.ac.uk/10.3747/co.22.2741

Chicago/Turabian Style

Beca, J., and K.K.W. Chan. 2016. "Cost-Effectiveness of Pazopanib: An Example of Improved Transparency and Accessibility of Industry-Sponsored Economic Evaluations through Publication in Peer-Reviewed Journals" Current Oncology 23, no. 4: 327-329. https://0-doi-org.brum.beds.ac.uk/10.3747/co.22.2741

Article Metrics

Back to TopTop